

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,
Patent Owner.

Case No. IPR2018-01675
Patent No. 8,603,044

**PETITIONER'S MANDATORY CHANGE-OF-INFORMATION NOTICES
UNDER 37 C.F.R. § 42.8(a)(3)**

Case No. IPR2018-01675
Patent No. 8,603,044

Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”), hereby submits the following updated notices in connection with the petition for *inter partes* review of U.S. Patent No. 8,603,044, Case IPR2018-01675.

A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Revised

Mylan’s real parties-in-interest are Mylan Pharmaceuticals Inc., Mylan Inc., and Mylan GmbH (Mylan N.V. subsidiaries); Biocon Research Ltd. and Biocon Ltd.; and Becton, Dickinson and Company.

B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised

The ’044 patent has been asserted in *Sanofi-Aventis U.S. LLC, et al. v. Mylan GmbH, et al.*, No. 2:17-cv-09105 (D.N.J.), filed October 24, 2017. Mylan and Biocon entities listed above are parties to this litigation. Becton Dickinson and Company supplies pens to Mylan, but has not been named as a party.

The ’044 patent also has been asserted in *Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp.*, No. 1:16-cv-00812 (D. Del.) and in *Sanofi -Aventis U.S. LLC v. Eli Lilly and Co.*, No. 14-cv-113 (D. Del.) (consent judgment). See EX1029 (*Markman* opinion in *Merck*); EX1030 (*Markman* opinion in *Eli Lilly*). The real parties-in-interest are not parties to these litigations.

Mylan has filed IPR2018-01676 also challenging claims 11, 14, 15, 18 and 19 of the ’044 patent. Mylan has filed IPR2018-01670, IPR2018-01677, IPR2018-01678,

Case No. IPR2018-01675

Patent No. 8,603,044

IPR2018-01679, IPR2018-01680, IPR2018-01682, IPR2018-01684, IPR2018-01696,
and IPR2019-00122 against related patents.

C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Unchanged

D. Electronic Service - Unchanged

Petitioner consents to electronic service by email at the email addresses
provided above.

Respectfully submitted,

Date: 30 October 2018

/ Richard Torczon /

Richard Torczon, Lead Counsel

Reg. No. 34,448

Case No. IPR2018-01675

Patent No. 8,603,044

CERTIFICATE OF SERVICE

I certify that the foregoing Petitioner's Mandatory Change-of-Information Notices under 37 C.F.R. § 42.8(a)(3) was served on 30 October 2018, on the Patent Owner at the email correspondence address of the Patent Owner as follows:

Elizabeth Stotland Weiswasser elizabeth.weiswasser@weil.com

Anish R. Desai anish.desai@weil.com

Kathryn M. Kantha kathryn.kantha@weil.com

William S. Ansley sutton.ansley@weil.com

Matthew D. Sieger matthew.sieger@weil.com

WEIL, GOTSHAL & MANGES LLP Sanofi.IPR.Service@weil.com

Respectfully submitted,

Date: 30 October 2018

/ Richard Torczon /
Richard Torczon, Lead Counsel
Reg. No. 34,448